AU2019208025A1 - Anti-Siglec-7 antibodies having reduced effector function - Google Patents

Anti-Siglec-7 antibodies having reduced effector function Download PDF

Info

Publication number
AU2019208025A1
AU2019208025A1 AU2019208025A AU2019208025A AU2019208025A1 AU 2019208025 A1 AU2019208025 A1 AU 2019208025A1 AU 2019208025 A AU2019208025 A AU 2019208025A AU 2019208025 A AU2019208025 A AU 2019208025A AU 2019208025 A1 AU2019208025 A1 AU 2019208025A1
Authority
AU
Australia
Prior art keywords
antibody
siglec
region
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019208025A
Other languages
English (en)
Inventor
Christopher Bebbington
Wouter Korver
Nenad Tomasevic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allakos Inc
Original Assignee
Allakos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allakos Inc filed Critical Allakos Inc
Publication of AU2019208025A1 publication Critical patent/AU2019208025A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2019208025A 2018-01-11 2019-01-11 Anti-Siglec-7 antibodies having reduced effector function Abandoned AU2019208025A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862616317P 2018-01-11 2018-01-11
US62/616,317 2018-01-11
PCT/US2019/013316 WO2019140273A1 (en) 2018-01-11 2019-01-11 Anti-siglec-7 antibodies having reduced effector function

Publications (1)

Publication Number Publication Date
AU2019208025A1 true AU2019208025A1 (en) 2020-09-03

Family

ID=67219179

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019208025A Abandoned AU2019208025A1 (en) 2018-01-11 2019-01-11 Anti-Siglec-7 antibodies having reduced effector function

Country Status (6)

Country Link
US (1) US11912766B2 (https=)
EP (1) EP3737410A4 (https=)
JP (1) JP7342005B2 (https=)
AU (1) AU2019208025A1 (https=)
CA (1) CA3087968A1 (https=)
WO (1) WO2019140273A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180054639A (ko) 2015-08-28 2018-05-24 알렉터 엘엘씨 항-siglec-7 항체 및 이의 사용 방법
CN119841953A (zh) * 2018-06-08 2025-04-18 艾利妥 抗siglec-7抗体及其使用方法
WO2023091512A2 (en) * 2021-11-16 2023-05-25 Allakos, Inc. Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9
WO2023192992A2 (en) * 2022-03-31 2023-10-05 The Wistar Institute Of Anatomy And Biology Bispecific natural killer engagers that target siglec-7
AU2023243622A1 (en) * 2022-03-31 2024-11-14 The Wistar Institute Of Anatomy And Biology Antibodies against human siglec-7 and use thereof for immunotherapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070244038A1 (en) 2006-04-12 2007-10-18 The Regents Of The University Of California Methods for treating lymphocyte-associated disorders by modulation of siglec activity
EP2172483A4 (en) 2007-07-04 2010-08-04 Forerunner Pharma Res Co Ltd ANTI-MUC17 ANTIBODY
BR112014020826A8 (pt) 2012-02-24 2017-09-19 Stem Centrx Inc Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco – anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
ES2791183T3 (es) 2012-12-21 2020-11-03 Aveo Pharmaceuticals Inc Anticuerpos anti-GDF15
MX383594B (es) * 2014-08-07 2025-03-14 Daiichi Sankyo Co Ltd Anticuerpo anti-orai1.
WO2016038064A1 (en) * 2014-09-10 2016-03-17 Innate Pharma Cross reactive siglec antibodies
KR20180054639A (ko) * 2015-08-28 2018-05-24 알렉터 엘엘씨 항-siglec-7 항체 및 이의 사용 방법
AU2016356780A1 (en) * 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
AU2017207807A1 (en) 2016-01-12 2018-07-12 Palleon Pharmaceuticals Inc. Use of Siglec-7 or Siglec-9 antibodies for the treatment of cancer
EP3426688A1 (en) 2016-03-08 2019-01-16 Innate Pharma Siglec neutralizing antibodies
BR112019002331A2 (pt) * 2016-08-05 2019-06-18 Allakos Inc anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos

Also Published As

Publication number Publication date
US11912766B2 (en) 2024-02-27
EP3737410A4 (en) 2022-04-20
JP7342005B2 (ja) 2023-09-11
JP2021511298A (ja) 2021-05-06
WO2019140273A1 (en) 2019-07-18
US20210054072A1 (en) 2021-02-25
EP3737410A1 (en) 2020-11-18
CA3087968A1 (en) 2019-07-18

Similar Documents

Publication Publication Date Title
US11773162B2 (en) Anti-Siglec-7 antibodies for the treatment of cancer
RU2733315C2 (ru) Комбинированная терапия для лечения злокачественной опухоли
US11912766B2 (en) Anti-Siglec-7 antibodies having reduced effector function
CA3100829A1 (en) Antibodies specific for gucy2c and uses thereof
IL293926A (en) Antibodies specific for cd47, pd-l1, and uses thereof
AU2019274654B2 (en) Antibodies specific for CD3 and uses thereof
EP3423495A1 (en) Antibodies specific to human poliovirus receptor (pvr)
JP2017507953A (ja) 抗ｃｄ３８抗体との併用療法
US20240209061A1 (en) Fusion proteins and uses thereof
CA2940865A1 (en) Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia
WO2021139682A1 (en) Anti-galectin-9 antibody and uses thereof
US20250042996A1 (en) Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9
RU2840501C1 (ru) Анти-галектин-9 антитело и его применение
HK40001896B (en) Antibodies specific to human poliovirus receptor (pvr)
HK40001896A (en) Antibodies specific to human poliovirus receptor (pvr)
EA040870B1 (ru) Варианты комбинированной терапии с антителами анти-cd38

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application